Chicago, ILNCT05671887Now EnrollingIRB Ready

Lung Cancer Clinical Trial in Chicago, IL

Access cutting-edge lung cancer treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Northwestern University

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access lung cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related lung cancer treatment provided free

Apply for This Chicago Location

Check if you qualify for this lung cancer clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Lung Cancer Study in Chicago

This is a prospective observational registration trial for patients who undergo lung transplantation for the treatment of the select groups of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.

Sponsor: Northwestern University

Who Can Participate

Inclusion Criteria

Any patient who is undergoing double lung transplantation as part of the clinical program, consents for this prospective observational trial, and has one of the following conditions will be eligible.
Common Inclusion Criteria
Adults of Age ≦ 80
Resistant or refractory to or without available standard of care treatment options or experimental treatment options that are known to increase survival outcome
Patients without any extrapulmonary disease
Patients with good general health with an ability to withstand physiologic stressors and undergo psychosocial evaluation by the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) or other assessment tools
Patients to meet all other criteria for lung transplantation including insurance approval and United Network for Organ Sharing (UNOS) registration Inclusion Criteria for Cohort A
Histologically confirmed selected lung non-small cell lung cancer including but not limited to: o according to the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification \- Lepidic dominant pattern
Adenocarcinoma in situ
Minimally invasive adenocarcinoma
Non mucinous lepidic predominant invasive adenocarcinoma o based on 2015 World Health Organization (WHO) classification of lung tumors including \- Invasive mucinous adenocarcinoma
Mixed invasive mucinous and mucinous adenocarcinoma
Colloid adenocarcinoma
Enteric adenocarcinoma
Minimally invasive adenocarcinoma
Nonmucinous
Mucinous \- Preinvasive lesions
Atypical adenomatous hyperplasia
Adenocarcinoma in situ
Nonmucinous
based on the 2004 WHO classification of lung tumors including - Bronchioloalveolar carcinoma
Nonmucinous
Mixed nonmucinous and mucinous or indeterminate
Without any distant metastasis confirmed by standard staging work-up
Without brain metastasis confirmed by brain imaging
Without unidentified primary site of cancer Inclusion Criteria for Cohort B
Metastatic cancers to lung alone - including but not limited to germ cell tumors, head \& neck tumors, colorectal tumors, renal cell tumors, testicular cancer
Without any other distant metastasis confirmed by standard staging work-up Inclusion Criteria for Cohort C
Respiratory failure with a history of cancer in the last 5 years - including, but not limited to interstitial lung disease (ILD), pulmonary fibrosis (idiopathic or secondary), advanced chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, cystic fibrosis (CF), emphysema due to alpha-1 antitrypsin deficiency, and pulmonary arterial hypertension (PAH)
Without any other distant metastasis confirmed by standard staging work-up

Exclusion Criteria

Adults unable or unwilling to consent
Individuals who are not yet adults (infants, children, teenagers)
Pregnant women
Vulnerable Populations
Presence of extrapulmonary disease or mediastinal nodal disease at the time of transplant referral
Small Cell Cancers
Unidentified primary site of cancer for Cohort A
Progression of disease or confirmed distant metastases or mediastinal nodal disease at any point during transplantation work-up
Medical ineligibility for lung transplantation after multidisciplinary assessment
Not a suitable candidate according to the lung transplantation protocol for treatment of lung confined primary or metastatic tumors
Body mass index more than 35 kg/m2
Evidence of co-existing malignancies for Cohort A
Untreatable significant dysfunction of another major organ system including heart, liver, kidney, or brain unless combined organ transplantation can be performed
Uncorrected atherosclerotic disease with suspected or confirmed end-organ ischemia or dysfunction and/or coronary artery disease not amenable to revascularization
Uncorrectable bleeding diathesis
Evidence of active Mycobacterium tuberculosis infection
Significant chest wall or spinal deformity expected to cause severe restriction after transplantation

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT05671887) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Lung Cancer Treatment Options in Chicago, IL

If you're searching for lung cancer treatment options in Chicago, IL, this clinical trial (NCT05671887) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all lung cancer clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Chicago, IL

See all lung cancer clinical trials recruiting in Chicago — not just this study.

Browse Lung Cancer Trials in Chicago →

Browse More Trials by Condition

Lung Cancer TrialsSmall Cell Lung Cancer TrialsNon-Small Cell Lung Cancer TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL